Ved Srivastava
Chief Technology Officer Perpetual Medicines
Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics. He joined Perpetual from Aktis Oncology. He was instrumental in the development of several peptide-based drugs, including Byetta?, Symlin? and Bydureon?. He has served as Head of Peptide Chemistry at both GlaxoSmithKline and Amylin Pharmaceuticals. He was also a co-founder at Phoundry Pharma and Vice President of Chemistry at both Intarcia and Aktis. Ved is a former president of the American Peptide Society (APS).
Seminars
Wednesday 2nd December 2026
Modern Amylin Molecules: Beyond Fibrillation Toward Developable Therapeutics
9:30 am
- Review how early fibrillation challenges were addressed through sequence modification and alternative peptide backbones
- Examine the remaining trade-offs between stability, aggregation, receptor pharmacology, concentration, formulation and manufacturability
- Separate developability challenges of therapeutic analogues from the biological significance of endogenous amylin aggregation in diabetes and other diseases
